Chromium supplementation in non-obese non-diabetic subjects is associated with a decline in insulin sensitivity.

ABSTRACT:

Unlabelled

Background

The use of chromium supplements is widespread for the prevention and treatment of diabetes mellitus but there are conflicting reports on efficacy, possibly reflecting discrepant effects across different populations. In the present studies, we test the hypothesis that chromium supplementation raises serum chromium levels and correspondingly improves insulin sensitivity.

Methods

A double blind placebo-controlled randomized trial was conducted on 31 non-obese, normoglycemic subjects. After baseline studies, the subjects were randomized to placebo or chromium picolinate 500 μg twice a day. The primary endpoint was change in insulin sensitivity as measured by euglycemic hyperinsulinemic clamp. Pre-specified secondary endpoints included fasting lipids

SUBMITTER: Masharani U 

PROVIDER: S-EPMC3537689 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature